scispace - formally typeset
M

Michelle P. McIntosh

Researcher at Monash University

Publications -  82
Citations -  2497

Michelle P. McIntosh is an academic researcher from Monash University. The author has contributed to research in topics: Population & Pharmacokinetics. The author has an hindex of 26, co-authored 82 publications receiving 2130 citations. Previous affiliations of Michelle P. McIntosh include University of Kansas & University of Liverpool.

Papers
More filters
Journal ArticleDOI

Miniature inhalation therapy platform using surface acoustic wave microfluidic atomization.

TL;DR: Control offered over the aerosol size, low power requirements, high delivery efficiency, and the miniaturization of the system together suggest the proposed platform represents an attractive alternative to current nebulizers compatible with microfluidic technologies.
Journal ArticleDOI

Lipid Digestion as a Trigger for Supersaturation: Evaluation of the Impact of Supersaturation Stabilization on the in Vitro and in Vivo Performance of Self-Emulsifying Drug Delivery Systems

TL;DR: The data suggest that digestion acts as a "trigger" for enhanced supersaturation and that solubilization/precipitation behavior is correlated with the degree of supersaturation on dispersion (S(M)DISP) or digestion (S (M)DIGEST).
Journal ArticleDOI

The effect of amino acid excipients on morphology and solid-state properties of multi-component spray-dried formulations for pulmonary delivery of biomacromolecules

TL;DR: The results suggest that with suitable particle size, good dispersibility and solid-state properties, selected trehalose/leucine combinations appear to have good potential for development into a universal carrier platform for pulmonary delivery of potent biomacromolecules.
Journal ArticleDOI

New developments in dry powder pulmonary vaccine delivery

TL;DR: The current understanding of pulmonary immunization is described, including possible barriers facing the development of pulmonary vaccines, and recent advances in spray-drying technologies applicable to the production of dry powder formulations for pulmonary vaccine delivery are discussed.